Case | Eye | DME management | Ocular co-morbidity management | ||
---|---|---|---|---|---|
Majority clinician response | Majority AI response | Majority clinician response | Majority AI response | ||
1 | RE | ML | OBS | OBS | OBS |
LE | IVA | IVA | OBS | OBS | |
2 | RE | ML | ML | PRP | PRP |
LE | ML | ML | PRP | PRP | |
3 | RE | OBS | OBS | OBS | OBS |
LE | OBS | OBS | OBS | OBS | |
4 | RE | OBS | OBS | OBS | OBS |
LE | OBS | IVA | PRP | OBS | |
5 | RE | OBS | OBS | OBS | OBS |
LE | ML | ML | OBS | OBS | |
6 | RE | OBS | OBS | OBS | OBS |
LE | IVA | IVA | OBS | OBS | |
7 | RE | IVA | IVA | OBS | CAT |
LE | OBS | IVA | OBS | OBS | |
8 | RE | IVS | IVA | PRP | OBS |
LE | OBS | OBS | PRP | OBS | |
9 | RE | ML | ML | OBS | OBS |
LE | ML | ML | OBS | OBS | |
10 | RE | IVS | IVA | OBS | OBS |
LE | IVS | IVA | OBS | OBS | |
11 | RE | OBS | OBS | OBS | OBS |
LE | OBS | OBS | OBS | OBS | |
12 | RE | IVA | IVA | OBS | OBS |
LE | OBS | OBS | OBS | OBS | |
13 | RE | OBS | OBS | OBS | OBS |
LE | OBS | OBS | OBS | OBS | |
14 | RE | OBS | OBS | OBS | OBS |
LE | OBS | OBS | OBS | OBS | |
15 | RE | IVA | IVA | OBS | OBS |
LE | IVA | IVA | OBS | OBS | |
16 | RE | IVS | ML | OBS | OBS |
LE | OBS | OBS | OBS | OBS | |
17 | RE | OBS | IVA | PRP | OBS |
LE | OBS | OBS | PRP | PRP | |
18 | RE | OBS | OBS | OBS | OBS |
LE | OBS | OBS | OBS | OBS | |
19 | RE | IVA | IVA | OBS | OBS |
LE | IVA | IVA | OBS | OBS | |
20 | RE | OBS | OBS | OBS | OBS |
LE | OBS | OBS | OBS | OBS | |
21 | RE | IVA | IVA | OBS | OBS |
LE | OBS | OBS | OBS | OBS | |
22 | RE | IVS | IVA | OBS | OBS |
LE | OBS | OBS | OBS | OBS | |
23 | RE | IVA | IVA | OBS | OBS |
LE | IVA | IVA | PRP | CAT | |
24 | RE | OBS | OBS | OBS | OBS |
LE | OBS | OBS | OBS | OBS | |
25 | RE | IVA | IVA | OBS | OBS |
LE | IVA | IVA | OBS | OBS |